对于具有较低瘤负担的晚期泌尿腺癌的avelumab维持疗法
Nobuki Furubayashi1, Jiro Tsujita1, Azusa Takayama1
1Department of Urology, NHO Kyushu Cancer Center, Fukuoka 811-1395, Japan.
Cancers
|August 14, 2025
概括
低瘤负担,仅由淋巴结转移表明,显著提高了晚期泌尿腺癌 (UC) 患者的长期存活率,在化疗后接受阿维卢马布维持治疗. 这一发现有助于高级UC治疗决策的风险分层.
科学领域:
- 在瘤学瘤学.
- 尿癌研究 尿癌研究
- 癌症转移研究 癌症转移研究
背景情况:
- 低瘤负担,通常以有限的转移部位为特征,与许多癌症的更好的结果有关.
- 在接受阿维卢马布维持治疗的晚期泌尿腺癌 (UC) 中,瘤负担的预后值需要进一步澄清.
研究的目的:
- 调查转移性模式的预后意义,作为瘤负担的替代品,在接受阿维卢马布维持治疗的晚期UC患者中.
- 评估仅淋巴结和非内脏转移模式对生存结果的影响.
主要方法:
- 对26名晚期UC患者的回顾性分析,这些患者接受了avelumab维护后的第一线基化疗.
- 患者根据化疗开始时的转移模式进行分类:只有淋巴结,非内脏或内脏疾病.
- 使用Kaplan-Meier分析评估了生存结果,包括无进展生存 (PFS) 和整体生存 (OS).
主要成果:
- 46.2%的患者仅发生淋巴结转移,57.7%患有非内脏性疾病.
- 从阿维卢马布开始的PFS和OS中位数分别为5.6个月和21.7个月.
- 只有淋巴结转移的患者在开始化疗后的生存期显著长 (41.1 vs 22.9 个月,p=0.044);根据转移模式,没有观察到PFS或AVELUMAB开始后的生存期的显著差异.
结论:
- 只有淋巴结的转移,表明瘤负担较低,与接受avelumab维护的晚期UC患者的长期生存显著改善有关.
- 基线瘤负担和转移模式对于高级UC维持治疗中的风险分层和共享决策非常有价值.
相关概念视频
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Urinary Tract Calculi III: Medical Management
23
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
23
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


